Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.

< BACK TO ARCHIVE


Papers: 25 Apr 2020 - 1 May 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Apr 25


J Headache Pain


http://www.ncbi.nlm.nih.gov/pubmed/32334534?dopt=Abstract


21


1

Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.

Authors

Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.
Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, Tiseo C, Pistoia F, Sacco S
J Headache Pain. 2020 Apr 25; 21(1):40.
PMID: 32334534.

Abstract

Treatment with onabotulinumtoxin A (BT-A) is safe and effective for chronic migraine (CM). Several studies assessed possible predictors of response to treatment with BT-A, but there is little knowledge on the frequency and predictors of sustained response. The aim of this study was to evaluate sustained response to BT-A in patients with CM.
Read This Paper